Wedbush Reiterates Outperform on Zenas BioPharma, Maintains $45 Price Target

Benzinga Newsdesk www.benzinga.com Negative 89.1%

Neg 89.1% Neu 0% Pos 0%

Wedbush analyst Martin Fan reiterates Zenas BioPharma (NASDAQ:ZBIO) with a Outperform and maintains $45 price target.

Comments

No comments yet. Be the first!